
Wednesday, April 30, 2025 | 12:30 pm PT / 3:30 pm ET
Featuring:
Jamie S. Lin, MD
Assistant Professor
Section of Nephrology
The University of Texas, MD Anderson Cancer Center
Niyati Jhaveri, PhD
Manager, Technology Access Program
Alamar Biosciences
Join experts from MD Anderson Cancer Center and Alamar Biosciences as they present new research on predictive biomarkers of immune-related adverse events (irAEs) using advanced NULISAseq™ proteomic technology.
This session will feature Dr. Niyati Jhaveri, Manager of the Technology Access Program at Alamar Biosciences, presenting recent data from a longitudinal CAR-T toxicity study conducted in collaboration with Cleveland Clinic through Alamar’s Technology Access Program (TAP). Her talk will highlight how high-sensitivity NULISAseq™ assays reveal temporal patterns of biomarker responses mediating CAR-T-associated toxicities.
Dr. Jamie Lin, Assistant Professor, Section of Nephrology at MD Anderson Cancer Center, will follow with findings from a study leveraging NULISA technology to identify a non-invasive urine proteomic signature for diagnosing ICI-associated nephritis.
Gain insight into cutting-edge biomarker research in immuno-oncology, and see how high-sensitivity proteomics is advancing early, non-invasive, and precise prediction of immune-related toxicities. Register today!

